Diffusion-weighted imaging and magnetization transfer imaging of tardive and edentulous orodyskinesia

Movement Disorders

Volumn 23, Issue 9, 2008, Pages 1281-1285

  Khiat, Abdesslem ^a   Kuznetsov, Yevgenity ^a   Blanchet, Pierre J ^a,b   Boulanger, Yvan ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antidepressants; Basal ganglia; Diffusion weighted imaging; Edentulous orodyskinesia; Magnetization transfer imaging; Tardive dyskinesia

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR BLOCKING AGENT;

AGED; ANATOMICAL VARIATION; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; EDENTULOUSNESS; FEMALE; GLOBUS PALLIDUS; HUMAN; INTERMETHOD COMPARISON; MALE; NERVE CELL LESION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OROFACIAL DYSKINESIA; PATHOLOGICAL ANATOMY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PUTAMEN; TARDIVE DYSKINESIA;

AGED; AGED, 80 AND OVER; AKATHISIA, DRUG-INDUCED; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MOUTH, EDENTULOUS; MOVEMENT DISORDERS;

EID: 52649091876     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22081     Document Type: Article

References (32)

1. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. II. Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50:703-714.
2. Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997;7:207-212.
3. Hedenmalm K, Guzey C, Dahl ML, Yue QY, Spigset O, Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymolphisms. J Clin Psychopharmacol 2006;26:192-197.
4. Kane JM, Woemer M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Psychopharmacology Suppl 1985;2:72-78.
5. Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry 2000;34:355-369.
6. Bailey LG, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull 1997;33:177-181.
7. Koller WC. Edentulous orodyskinesia. Ann Neurol 1983;13:97-99.
8. Mion CC, Andreasen NC, Arndt S, Swayze VW, II, Cohen GA. MRI abnormalities in tardive dyskinesia. Psychiatry Res 1991; 40:157-166.
9. Dalgalarrondo P, Gattaz WF. Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration of neuroleptic treatment. Eur Arch Psychiatry Clin Neurosci 1994;244:272-277.
10. Brown KW, White T, Wardlaw JM, Walker N, Foley D. Caudate nucleus morphology in tardive dyskinesia. Br J Psychiatry 1996; 169:631-636.
11. McCreadie RG, Thara R, Padmavati R, Srinivasan TN, Jaipurkar SD. Structural brain differences between never-treated patients with schizophrenia, with and without dyskinesia, and normal control subjects: a magnetic resonance imaging study. Arch Gen Psychiatry 2002;59:332-336.
12. Bartzokis G, Garber HJ, Marder SR, Olendorf WH. MRI in tardive dyskinesia: shortened left caudate T2. Biol Psychiatry 1990;28:1027-1036.
13. Buckley P, O'Callaghan E, Mulvany F, et al. Basal ganglia T2 relaxation times in schizophrenia: a quantitative magnetic resonance imaging study in relation to tardive dyskinesia. Psychiatry Res 1995;61:95-102.
14. Elkashef AM, Buchanan RW, Gellad F, Munson RC, Breier A. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. Am J Psychiatry 1994;151:752-755.
15. Ando K, Takei N, Matsumoto H, Iyo M, Isoda H, Mori N. Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy. Schizophr Res 2002;57:273-279.
16. Kuznetsov Y, Khiat A, Blancher PJ, Boulanger Y. Proton magnetic resonance spectroscopy study of dyskinesia patients. Mov Disord 2007;22:957-962.
17. Mascalchi M, Filippi M, Floris R, Fonda C, Gasparotti R, Villari N. Diffusion-weighted MR of the brain: methodology and clinical application. Radiol Med (Torino) 2005;109:155-197.
18. Horsfield MA, Magnetization transfer imaging in multiple sclerosis. J Neuroimaging 2005;15 (4 Suppl):58S-67S.
19. Lokau M, Adams J, Troiano A, Stoessl A. Neuroimaging in Parkinson's disease. J Neural Transm. Suppl 2006;70:241-248.
20. Eckert T, Sailer M, Kaufmann J, et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004;21:229-235.
21. Seppi K, Schocke MF, Prennschuetz-Schuetzenau K, et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord 2006;21:847-852.
22. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-927.
23. Ahlhelm F, Hagen T, Schneider O, Dorenbeck U, Nabhan A, Reith W. ADC mapping of normal human brain. Med Sci Monit 2004;10:MT121-MT125.
24. Helenius J, Soinne L, Perkio J, et al. Diffusion-weighted MR imaging in normal human brains in various age groups. AJNR Am J Neuroradiol 2002;23:194-199.
25. Armstrong CL, Traipe E, Hunter JV, et al. Age-related, regional, hemispheric, and medial-lateral differences in myelin integrity in vivo in the normal adult brain. AJNR Am J Neuroradiol 2004; 25:977-984.
26. Andreone N, Tansella M, Cerini R, et al. Cortical white-matter microstructure in schizophrenia. Diffusion imaging study. Br J Psychiatry 2007;191:113-119.
27. Brambilla P, Cerini R, Gasparini A, et al. Investigation of corpus callosum in schizophrenia with diffusion imaging. Schizophr Res 2005;79:201-210.
28. Kubicki M, Park H, Westin CF, et al. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 2005;26:1109-1118.
29. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. I. Pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50:541-547,
30. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004;65 (Suppl 9):25-28.
31. Burger M, Fachinetto R, Calegari L, Paixao MW, Braga AL, Rocha JB. Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide. Brain Res Bull 2004;64:339-345.
32. Mascalchi M, Lolli F, Della Nave R, et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004;232:867-873.